CCK8 data revealed that low concentrations of the two GSK inhibitors specifically inhibited the proliferation of leukemia cells with FLT3-ITD mutations as early as 24 h after treatment but had no effect on MLL-rearranged AML cells (Fig. 2A–H). The gene discussed is KMT2A; the disease is leukemia.